Contract Research Services

WACKER is pleased to introduce Contract Research Services (CRS) from our Biotechnology R&D Center in Munich, Germany. Our CRS enable a continuous path from early-stage pre-clinical to clinical and commercial supply spanning pDNA, RNA and LNPs.

The services we offer include:

Lead development & optimization
Initial process optimization for GMP manufacturability & scalability
Analytical characterization & stability testing
Material supply for in vitro & preclinical studies
Tech transfer to process development
Regulatory & IP know-how

Key Benefits

A Seamless Path from Concept to Scale-Up & GMP
With CRS, WACKER can cost-effectively produce small quantities at R&D grade for in vitro and pre-clinical studies. Customer projects can then be later seamlessly scaled up with transfer to Wacker Biotech’s global network of manufacturing facilities for high-quality and GMP clinical or commercial supply.
Deep Nucleic Acids Expertise
In addition to mRNA and LNPs, the team of approximately 30 advanced therapy scientists at our state-of-the-art Biotechnology Center in Munich has extensive experience with various forms of RNA that underlie many novel advanced therapeutics and vaccines, including circular RNA (circRNA) and self-amplifying RNA (saRNA).
Strong R&D Track Record
Our formal CRS may be new in name, but our capabilities definitely are not . The team is the same expert R&D team responsible for PLASMITEC®, WACKER’s industry-leading platform featuring a superior E. coli K12 derivative strain for production of >90% supercoiled plasmid DNA at yields averaging 1 g/L. The team currently leads more than 35 active collaborations with academic and consortia partners. At least 100 biotechnology patents have resulted from work conducted at WACKER’s corporate R&D site in Munich.

WACKER Contract Research Services (CRS)

	R&D Quantity	Services Offered
pDNA	Up to 100 mg	Plasmid design & optimization pDNA production (shake flask or fermentation) pDNA DSP pDNA linearization (RNA templates) DNA analytics
RNA	Up to 100 mg	RNA design support (UTR, poly(A) tail, capping) RNA production (IVT) RNA DSP incl. extra low dsRNA content RNA in-house in vitro testing RNA analytics
LNP	Up to 10 mg encapsulated RNA	LNP formulation screening & development – in-house & partner lipids pre-selected for efficacy, stability & safety LNP production LNP DSP (TFF) LNP stability testing LNP in-house in vitro testing Targeted (tLNPs) / Conjugated LNPs LNP analytics

As an emerging biotech company, our development of new therapeutic approaches starts at a small scale. Our platform technology based on seRNAs (selectively expressed RNAs) can easily be adapted to numerous therapeutic areas by utilizing the transcriptome for selective cell targeting and fusogenic LNPs for organ-specific targeting. WACKER’s CRS help us to speed up the path from design to delivery.

Bernd Hoffmann, CEO/CSO and Co-founder, SRTD Biotech GmbH